[ Skip Navigation ]
 
 

Michael Stevens

Member, Board of Directors

Michael Stevens is currently a Director of Oxford-Emergent Tuberculosis Consortium (OETC) Limited, a UK based joint venture between the University of Oxford and Emergent Biosolutions Inc to develop the world’s most clinically advanced tuberculosis vaccine – MVA85A, and a member of the Advisory Board of Chiesi Farmaceutici SpA, a private Italian international pharmaceutical group. In addition, he is a business advisor to the Chief Executive Officer of Gedeon Richter Ltd., Hungary. Until his retirement in July 2005, Mr. Stevens was Executive Vice President at GE Healthcare and previously was Corporate Development Director of Amersham Plc. During his career he held senior positions at major pharmaceutical companies, notably Gedeon Richter Ltd., Wellcome Plc, and Syntex Corporation in California. Mr. Stevens is a Fellow of the Chartered Institute of Management Accountants and has studied at INSEAD business school in France.

Share This Page: